{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:30:17Z","timestamp":1792287017082,"version":"4.4.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T00:00:00Z","timestamp":1181001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T00:00:00Z","timestamp":1181001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1038\/sj.tpj.6500462","type":"journal-article","created":{"date-parts":[[2007,6,12]],"date-time":"2007-06-12T10:20:39Z","timestamp":1181643639000},"page":"4-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["The clinical role of genetic polymorphisms in drug-metabolizing enzymes"],"prefix":"10.1038","volume":"8","author":[{"given":"D","family":"Tomalik-Scharte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Fuhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Kirchheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,6,5]]},"reference":[{"key":"BF6500462_CR1","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s00115-005-1915-8","volume":"76","author":"J Kirchheiner","year":"2005","unstructured":"Kirchheiner J, Sasse J, Roots I, Brockmoller J, Bauer M . The value of pharmacogenetic tests in antidepressive medication therapy. Nervenarzt 2005; 76: 1340\u20131354.","journal-title":"Nervenarzt"},{"key":"BF6500462_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1176\/appi.psy.47.1.75","volume":"47","author":"J de Leon","year":"2006","unstructured":"de Leon J, Armstrong SC, Cozza KL . Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006; 47: 75\u201385.","journal-title":"Psychosomatics"},{"key":"BF6500462_CR3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(56)92065-7","volume":"2","author":"W Kalow","year":"1956","unstructured":"Kalow W . Familial incidence of low pseudocholinesterase level. Lancet 1956; 2: 576\u2013577.","journal-title":"Lancet"},{"key":"BF6500462_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/15622970209150599","volume":"3","author":"M Bauer","year":"2002","unstructured":"Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ . World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5\u201343.","journal-title":"World J Biol Psychiatry"},{"issue":"Suppl 1","key":"BF6500462_CR5","first-page":"5","volume":"64","author":"JC Nelson","year":"2003","unstructured":"Nelson JC . Managing treatment-resistant major depression. J Clin Psychiatry 2003; 64 (Suppl 1): 5\u201312.","journal-title":"J Clin Psychiatry"},{"key":"BF6500462_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/00004850-198604000-00002","volume":"1","author":"P Baumann","year":"1986","unstructured":"Baumann P, Jonzier Perey M, Koeb L, K\u00fcpfer A, Tinguely D, Schopf J . Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986; 1: 102\u2013112.","journal-title":"Int Clin Psychopharmacol"},{"key":"BF6500462_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","volume":"53","author":"L Bertilsson","year":"2002","unstructured":"Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A . Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53: 111\u2013122.","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500462_CR8","first-page":"284","volume":"60","author":"C Sachse","year":"1997","unstructured":"Sachse C, Brockmoller J, Bauer S, Roots I . Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284\u2013295.","journal-title":"Am J Hum Genet"},{"key":"BF6500462_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/00008571-200110000-00004","volume":"11","author":"UM Zanger","year":"2001","unstructured":"Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001; 11: 573\u2013585.","journal-title":"Pharmacogenetics"},{"key":"BF6500462_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/00008571-199802000-00003","volume":"8","author":"EU Griese","year":"1998","unstructured":"Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8: 15\u201326.","journal-title":"Pharmacogenetics"},{"key":"BF6500462_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/sj.mp.4001494","volume":"9","author":"J Kirchheiner","year":"2004","unstructured":"Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442\u2013473.","journal-title":"Mol Psychiatry"},{"key":"BF6500462_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2515\/therapie:2004003","volume":"59","author":"K Brosen","year":"2004","unstructured":"Brosen K . Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 2004; 59: 5\u201312.","journal-title":"Therapie"},{"key":"BF6500462_CR13","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1592\/phco.22.12.1001.33603","volume":"22","author":"YW Lam","year":"2002","unstructured":"Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J . CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002; 22: 1001\u20131006.","journal-title":"Pharmacotherapy"},{"key":"BF6500462_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0009-9236(01)21861-X","volume":"70","author":"K Laine","year":"2001","unstructured":"Laine K, Tybring G, Hartter S, Andersson K, Svensson JO, Widen J et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 2001; 70: 327\u2013335.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s002280050261","volume":"52","author":"O Spigset","year":"1997","unstructured":"Spigset O, Granberg K, Hagg S, Norstrom A, Dahlqvist R . Relationship between fluvoxamine pharmacokinetics and CYP2D6\/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 1997; 52: 129\u2013133.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF6500462_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0009-9236(96)90134-4","volume":"60","author":"JA Carrillo","year":"1996","unstructured":"Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L . Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996; 60: 183\u2013190.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1365-2125.1998.00670.x","volume":"45","author":"O Spigset","year":"1998","unstructured":"Spigset O, Granberg K, Hagg S, Soderstrom E, Dahlqvist R . Non-linear fluvoxamine disposition. Br J Clin Pharmacol 1998; 45: 257\u2013263.","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500462_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/00004714-200106000-00013","volume":"21","author":"CB Eap","year":"2001","unstructured":"Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay K, Kosel M et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 2001; 21: 330\u2013334.","journal-title":"J Clin Psychopharmacol"},{"key":"BF6500462_CR19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/0028-3908(92)90100-4","volume":"31","author":"RW Fuller","year":"1992","unstructured":"Fuller RW, Snoddy HD, Krushinski JH, Robertson DW . Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology 1992; 31: 997\u20131000.","journal-title":"Neuropharmacology"},{"key":"BF6500462_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/clpt.1992.24","volume":"1","author":"SH Sindrup","year":"1992","unstructured":"Sindrup SH, Br\u00f8sen K, Gram LF . Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 1: 288\u2013295.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/01.jcp.0000145341.30547.f0","volume":"24","author":"J Kirchheiner","year":"2004","unstructured":"Kirchheiner J, Henckel HB, Meineke I, Roots I, Brockm\u00f6ller J . Impact of the CYP2D6 ultra-rapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 2004; 24: 647\u2013652.","journal-title":"J Clin Psychopharmacol"},{"key":"BF6500462_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1365-2125.1996.tb00173.x","volume":"41","author":"SV Otton","year":"1996","unstructured":"Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM . Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41: 149\u2013156.","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500462_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1046\/j.1365-2125.1999.00913.x","volume":"47","author":"T Fukuda","year":"1999","unstructured":"Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K et al. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 1999; 47: 450\u2013453.","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500462_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/00007691-200004000-00011","volume":"22","author":"AH Veefkind","year":"2000","unstructured":"Veefkind AH, Haffmans PM, Hoencamp E . Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000; 22: 202\u2013208.","journal-title":"Ther Drug Monit"},{"key":"BF6500462_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-2125.1994.tb04293.x","volume":"37","author":"L Firkusny","year":"1994","unstructured":"Firkusny L, Gleiter CH . Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. Br J Clin Pharmacol 1994; 37: 383\u2013388.","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500462_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0006-2952(85)90063-2","volume":"34","author":"G Gabris","year":"1985","unstructured":"Gabris G, Baumann P, Janzier-perey MPB, Woggon B, K\u00fcpfer A . N-methylation of maprotiline in debrisoquine\/mephenytoin-phenotyped depressive patients. Biochemical Pharmacology 1985; 34: 409\u2013410.","journal-title":"Biochemical Pharmacology"},{"key":"BF6500462_CR27","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0026-895X(24)12054-8","volume":"28","author":"SR Faucette","year":"2000","unstructured":"Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000; 28: 1222\u20131230.","journal-title":"Drug Metab Dispos"},{"key":"BF6500462_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1365-2125.1996.tb00051.x","volume":"42","author":"RH Barbhaiya","year":"1996","unstructured":"Barbhaiya RH, Buch AB, Greene DS . Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 1996; 42: 573\u2013581.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"BF6500462_CR29","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/S0924-977X(97)00417-3","volume":"7","author":"P Dostert","year":"1997","unstructured":"Dostert P, Benedetti MS, Poggesi I . Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997; 7 (Suppl 1): S23\u2013S35; discussion S71\u2013S73.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BF6500462_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1600-0447.1990.tb05347.x","volume":"360","author":"MP Schoerlin","year":"1990","unstructured":"Schoerlin MP, Blouin RA, Pfefen JP, Guentert TW . Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine. Acta Psychiatr Scand Suppl 1990; 360: 98\u2013100.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"BF6500462_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0924-977X(96)00023-5","volume":"6","author":"S H\u00e4rtter","year":"1996","unstructured":"H\u00e4rtter S, Dingemanse J, Baier D, Ziegler G, Hiemke C . The role of cytochrome P450 2D6 in the metabolism of moclobemide. Eur Neuropsychopharmacol 1996; 6: 225\u2013230.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BF6500462_CR32","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/0009-9236(95)90230-9","volume":"57","author":"LF Gram","year":"1995","unstructured":"Gram LF, Guentert TW, Grange S, Vistisen K, Br\u00f8sen K . Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995; 57: 670\u2013677.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s002130050376","volume":"133","author":"K Mihara","year":"1997","unstructured":"Mihara K, Otani K, Suzuki A, Yasui N, Nakano H, Meng X et al. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Psychopharmacology (Berl) 1997; 133: 95\u201398.","journal-title":"Psychopharmacology (Berl)"},{"key":"BF6500462_CR34","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.clpt.2003.12.015","volume":"75","author":"T Rau","year":"2004","unstructured":"Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004; 75: 386\u2013393.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR35","first-page":"329","volume":"60","author":"K Grasmader","year":"2004","unstructured":"Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60: 329\u2013336.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF6500462_CR36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00008571-199912000-00003","volume":"9","author":"E Lessard","year":"1999","unstructured":"Lessard E, Yessine M, Hamelin B, O\u2019Hara G, LeBlanc J, Turgeon J . Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9: 435\u2013443.","journal-title":"Pharmacogenetics"},{"key":"BF6500462_CR37","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S0009-9236(96)90148-4","volume":"60","author":"S Chen","year":"1996","unstructured":"Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996; 60: 522\u2013534.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1034\/j.1600-0447.2001.00299.x","volume":"104","author":"J Kirchheiner","year":"2001","unstructured":"Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173\u2013192.","journal-title":"Acta Psychiatr Scand"},{"key":"BF6500462_CR39","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1365-2125.1982.tb01982.x","volume":"14","author":"MS Lennard","year":"1982","unstructured":"Lennard MS, Silas JH, Freestone S, Trevethick J . Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1982; 14: 301\u2013303.","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500462_CR40","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/clpt.1983.242","volume":"34","author":"MS Lennard","year":"1983","unstructured":"Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF . Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther 1983; 34: 732\u2013737.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR41","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s002280050495","volume":"54","author":"R Koytchev","year":"1998","unstructured":"Koytchev R, Alken RG, Vlahov V, Kirkov V, Kaneva R, Thyroff Friesinger U et al. Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol. Eur J Clin Pharmacol 1998; 54: 469\u2013474.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF6500462_CR42","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1365-2125.1985.tb05112.x","volume":"20","author":"JC McGourty","year":"1985","unstructured":"McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF . Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. Br J Clin Pharmacol 1985; 20: 555\u2013566.","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500462_CR43","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1056\/NEJM198212163072505","volume":"307","author":"MS Lennard","year":"1982","unstructured":"Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF . Oxidation phenotype \u2013 a major determinant of metoprolol metabolism and response. N Engl J Med 1982; 307: 1558\u20131560.","journal-title":"N Engl J Med"},{"key":"BF6500462_CR44","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.clpt.2004.07.002","volume":"76","author":"J Kirchheiner","year":"2004","unstructured":"Kirchheiner J, Heesch C, Bauer S, Meisel C, Seringer A, Goldammer M et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2004; 76: 302\u2013312.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/BF01409476","volume":"38","author":"G Neugebauer","year":"1990","unstructured":"Neugebauer G, Akpan W, Kaufmann B, Reiff K . Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol 1990; 38: 108\u2013111.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF6500462_CR46","first-page":"970","volume":"25","author":"HG Oldham","year":"1997","unstructured":"Oldham HG, Clarke SE . In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(\u2212)-carvedilol. Drug Metab Dispos 1997; 25: 970\u2013977.","journal-title":"Drug Metab Dispos"},{"key":"BF6500462_CR47","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/0009-9236(95)90036-5","volume":"57","author":"HH Zhou","year":"1995","unstructured":"Zhou HH, Wood AJJ . Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995; 57: 518\u2013524.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/00912700122009746","volume":"41","author":"DW Graff","year":"2001","unstructured":"Graff DW, Williamson KM, Pieper JA, Carson SW, Adams Jr KF, Cascio WE et al. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J Clin Pharmacol 2001; 41: 97\u2013106.","journal-title":"J Clin Pharmacol"},{"key":"BF6500462_CR49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/00008571-200203000-00004","volume":"12","author":"J Kirchheiner","year":"2002","unstructured":"Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002; 12: 101\u2013109.","journal-title":"Pharmacogenetics"},{"key":"BF6500462_CR50","first-page":"207","volume":"23","author":"RA Stearns","year":"1995","unstructured":"Stearns RA, Chakravarty PK, Chen R, Chiu SH . Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995; 23: 207\u2013215.","journal-title":"Drug Metab Dispos"},{"key":"BF6500462_CR51","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0009-9236(99)70114-1","volume":"65","author":"JB McCrea","year":"1999","unstructured":"McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW et al. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-31. Clin Pharmacol Ther 1999; 65: 348\u2013352.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR52","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2002.121216","volume":"71","author":"U Yasar","year":"2002","unstructured":"Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002; 71: 89\u201398.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR53","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/0091270002239710","volume":"43","author":"CR Lee","year":"2003","unstructured":"Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA . Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 2003; 43: 84\u201391.","journal-title":"J Clin Pharmacol"},{"key":"BF6500462_CR54","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1097\/00004872-200210000-00030","volume":"20","author":"P Hallberg","year":"2002","unstructured":"Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (S0ILVHIA) trial. J Hypertens 2002; 20: 2089\u20132093.","journal-title":"J Hypertens"},{"key":"BF6500462_CR55","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.clpt.2003.08.001","volume":"74","author":"S Uchida","year":"2003","unstructured":"Uchida S, Watanabe H, Nishio S, Hashimoto H, Yamazaki K, Hayashi H et al. Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91\/3 genotype. Clin Pharmacol Ther 2003; 74: 505\u2013508.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR56","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.5858\/2004-128-1360-EOPITC","volume":"128","author":"DM Adcock","year":"2004","unstructured":"Adcock DM, Koftan C, Crisan D, Kiechle FL . Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation. Arch Pathol Lab Med 2004; 128: 1360\u20131363.","journal-title":"Arch Pathol Lab Med"},{"key":"BF6500462_CR57","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","volume":"45","author":"JO Miners","year":"1998","unstructured":"Miners JO, Birkett DJ . Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525\u2013538.","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500462_CR58","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1067\/mcp.2002.129321","volume":"72","author":"MG Scordo","year":"2002","unstructured":"Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R . Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702\u2013710.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR59","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","volume":"287","author":"MK Higashi","year":"2002","unstructured":"Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690\u20131698.","journal-title":"JAMA"},{"key":"BF6500462_CR60","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","volume":"353","author":"GP Aithal","year":"1999","unstructured":"Aithal GP, Day CP, Kesteven PJ, Daly AK . Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717\u2013719.","journal-title":"Lancet"},{"key":"BF6500462_CR61","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.clpt.2004.01.007","volume":"75","author":"H Takahashi","year":"2004","unstructured":"Takahashi H, Wilkinson GR, Padrini R, Echizen H . CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin:similarities yet differences. Clin Pharmacol Ther 2004; 75: 376\u2013380.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR62","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.clpt.2004.01.008","volume":"75","author":"S Morin","year":"2004","unstructured":"Morin S, Bodin L, Loriot MA, Thijssen HH, Robert A, Strabach S et al. Pharmacogenetics of acenocoumarol pharmacodynamics. Clin Pharmacol Ther 2004; 75: 403\u2013414.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR63","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.clpt.2003.12.017","volume":"75","author":"T Schalekamp","year":"2004","unstructured":"Schalekamp T, van Geest-Daalderop JH, de Vries-Goldschmeding H, Conemans J, Bernsen MjM, de Boer A . Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin Pharmacol Ther 2004; 75: 394\u2013402.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR64","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00008571-200401000-00003","volume":"14","author":"LE Visser","year":"2004","unstructured":"Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004; 14: 27\u201333.","journal-title":"Pharmacogenetics"},{"key":"BF6500462_CR65","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1160\/TH03-12-0741","volume":"92","author":"LE Visser","year":"2004","unstructured":"Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004; 92: 61\u201366.","journal-title":"Thromb Haemost"},{"key":"BF6500462_CR66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00008571-200401000-00002","volume":"14","author":"J Kirchheiner","year":"2004","unstructured":"Kirchheiner J, Ufer M, Walter EC, Kammerer B, Kahlich R, Meisel C et al. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics 2004; 14: 19\u201326.","journal-title":"Pharmacogenetics"},{"key":"BF6500462_CR67","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00228-003-0580-8","volume":"59","author":"E Hummers-Pradier","year":"2003","unstructured":"Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM . Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol 2003; 59: 213\u2013219.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF6500462_CR68","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.clpt.2004.08.006","volume":"76","author":"T Schalekamp","year":"2004","unstructured":"Schalekamp T, Oosterhof M, van Meegen E, van Der Meer FJ, Conemans J, Hermans M et al. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 2004; 76: 409\u2013417.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR69","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1182\/blood-2005-03-1108","volume":"106","author":"EA Sconce","year":"2005","unstructured":"Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329\u20132333.","journal-title":"Blood"},{"key":"BF6500462_CR70","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/sj.clpt.6100036","volume":"81","author":"T Schalekamp","year":"2007","unstructured":"Schalekamp T, Brasse BP, Roijers JF, van Meegen E, van der Meer FJ, van Wijk EM et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 2007; 81: 185\u2013193.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR71","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2141.2006.06007.x","volume":"133","author":"R Montes","year":"2006","unstructured":"Montes R, Ruiz de Gaona E, Martinez-Gonzalez MA, Alberca I, Hermida J . The c.\u22121639G&gt;A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 2006; 133: 183\u2013187.","journal-title":"Br J Haematol"},{"key":"BF6500462_CR72","first-page":"594","volume":"46","author":"SM De Morais","year":"1994","unstructured":"De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA . Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594\u2013598.","journal-title":"Mol Pharmacol"},{"key":"BF6500462_CR73","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1046\/j.1365-2125.1998.t01-1-00702.x","volume":"45","author":"T Andersson","year":"1998","unstructured":"Andersson T, Holmberg J, Rohss K, Walan A . Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1998; 45: 369\u2013375.","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500462_CR74","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1600-0773.2004.pto950102.x","volume":"95","author":"U Klotz","year":"2004","unstructured":"Klotz U, Schwab M, Treiber G . CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004; 95: 2\u20138.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"BF6500462_CR75","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1592\/phco.23.4.460.32128","volume":"23","author":"E Chong","year":"2003","unstructured":"Chong E, Ensom MH . Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23: 460\u2013471.","journal-title":"Pharmacotherapy"},{"key":"BF6500462_CR76","first-page":"595","volume":"57","author":"U Fuhr","year":"2002","unstructured":"Fuhr U, Jetter A . Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 2002; 57: 595\u2013601.","journal-title":"Pharmazie"},{"key":"BF6500462_CR77","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/00008571-200106000-00009","volume":"11","author":"T Furuta","year":"2001","unstructured":"Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Nakagawa K et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001; 11: 341\u2013348.","journal-title":"Pharmacogenetics"},{"key":"BF6500462_CR78","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1067\/mcp.2001.113959","volume":"69","author":"T Furuta","year":"2001","unstructured":"Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69: 158\u2013168.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR79","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.7326\/0003-4819-129-12-199812150-00006","volume":"129","author":"T Furuta","year":"1998","unstructured":"Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027\u20131030.","journal-title":"Ann Intern Med"},{"key":"BF6500462_CR80","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1517\/phgs.5.2.181.27483","volume":"5","author":"T Furuta","year":"2004","unstructured":"Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T . Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004; 5: 181\u2013202.","journal-title":"Pharmacogenomics"},{"key":"BF6500462_CR81","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000028398","volume":"61","author":"PJ Wedlund","year":"2000","unstructured":"Wedlund PJ . The CYP2C19 enzyme polymorphism. Pharmacology 2000; 61: 174\u2013183.","journal-title":"Pharmacology"},{"key":"BF6500462_CR82","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.clpt.2004.05.002","volume":"76","author":"M Schwab","year":"2004","unstructured":"Schwab M, Schaeffeler E, Klotz U, Treiber G . CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004; 76: 201\u2013209.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR83","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/j.1572-0241.2006.00717.x","volume":"101","author":"S Padol","year":"2006","unstructured":"Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH . The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006; 101: 1467\u20131475.","journal-title":"Am J Gastroenterol"},{"key":"BF6500462_CR84","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1515\/CCLM.2003.087","volume":"41","author":"M Oscarson","year":"2003","unstructured":"Oscarson M . Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine. Clin Chem Lab Med 2003; 41: 573\u2013580.","journal-title":"Clin Chem Lab Med"},{"key":"BF6500462_CR85","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00008571-199902000-00006","volume":"9","author":"ES Collie-Duguid","year":"1999","unstructured":"Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9: 37\u201342.","journal-title":"Pharmacogenetics"},{"key":"BF6500462_CR86","first-page":"651","volume":"32","author":"RM Weinshilboum","year":"1980","unstructured":"Weinshilboum RM, Sladek SL . Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651\u2013662.","journal-title":"Am J Hum Genet"},{"key":"BF6500462_CR87","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1200\/JCO.2001.19.8.2293","volume":"19","author":"WE Evans","year":"2001","unstructured":"Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293\u20132301.","journal-title":"J Clin Oncol"},{"key":"BF6500462_CR88","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/clpt.1987.4","volume":"41","author":"L Lennard","year":"1987","unstructured":"Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM . Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987; 41: 18\u201325.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR89","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1046\/j.1365-2141.1999.01416.x","volume":"105","author":"HL McLeod","year":"1999","unstructured":"McLeod HL, Coulthard S, Thomas AE, Pritchard SC, King DJ, Richards SM et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999; 105: 696\u2013700.","journal-title":"Br J Haematol"},{"key":"BF6500462_CR90","doi-asserted-by":"publisher","first-page":"608","DOI":"10.7326\/0003-4819-126-8-199704150-00003","volume":"126","author":"CR Yates","year":"1997","unstructured":"Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608\u2013614.","journal-title":"Ann Intern Med"},{"key":"BF6500462_CR91","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/0140-6736(93)93028-Y","volume":"341","author":"E Schutz","year":"1993","unstructured":"Schutz E, Gummert J, Mohr F, Oellerich M . Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341: 436.","journal-title":"Lancet"},{"key":"BF6500462_CR92","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/annurev.med.54.101601.152352","volume":"54","author":"R Nagasubramanian","year":"2003","unstructured":"Nagasubramanian R, Innocenti F, Ratain MJ . Pharmacogenetics in cancer treatment. Annu Rev Med 2003; 54: 437\u2013452.","journal-title":"Annu Rev Med"},{"key":"BF6500462_CR93","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0016-5085(00)70354-4","volume":"118","author":"JF Colombel","year":"2000","unstructured":"Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025\u20131030.","journal-title":"Gastroenterology"},{"key":"BF6500462_CR94","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s002280050457","volume":"54","author":"T Kroplin","year":"1998","unstructured":"Kroplin T, Weyer N, Gutsche S, Iven H . Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 1998; 54: 265\u2013271.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF6500462_CR95","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1053\/gast.2001.26927","volume":"121","author":"M Schwab","year":"2001","unstructured":"Schwab M, Schaeffeler E, Marx C, Zanger U, Aulitzky W, Eichelbaum M . Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only. Gastroenterology 2001; 121: 498\u2013499.","journal-title":"Gastroenterology"},{"key":"BF6500462_CR96","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1365-2125.1999.00884.x","volume":"47","author":"L Lennard","year":"1999","unstructured":"Lennard L . Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol 1999; 47: 131\u2013143.","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500462_CR97","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/clpt.1980.174","volume":"28","author":"PA Pazmino","year":"1980","unstructured":"Pazmino PA, Sladek SL, Weinshilboum RM . Thiol S-methylation in uremia: erythrocyte enzyme activities and plasma inhibitors. Clin Pharmacol Ther 1980; 28: 356\u2013367.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR98","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/08035259850158001","volume":"87","author":"JB Andersen","year":"1998","unstructured":"Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K . Pharmacokinetics, dose adjustments, and 6-mercaptopurine\/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998; 87: 108\u2013111.","journal-title":"Acta Paediatr"},{"key":"BF6500462_CR99","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/00007691-200404000-00018","volume":"26","author":"WE Evans","year":"2004","unstructured":"Evans WE . Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004; 26: 186\u2013191.","journal-title":"Ther Drug Monit"},{"key":"BF6500462_CR100","first-page":"289","volume-title":"A Clinical Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics","author":"G Milan","year":"1999","unstructured":"Milan G, Etienne MC . 5-Fluorouracil. In: Grochow LB, Ames MM (Hrsg) (eds.). A Clinical Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. Williams & Wilkins: Baltimore, 1999 pp 289\u2013300."},{"key":"BF6500462_CR101","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0165-6147(00)89065-3","volume":"16","author":"FJ Gonzalez","year":"1995","unstructured":"Gonzalez FJ, Fernandez-Salguero P . Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol Sci 1995; 16: 325\u2013327.","journal-title":"Trends Pharmacol Sci"},{"key":"BF6500462_CR102","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1172\/JCI118830","volume":"98","author":"X Wei","year":"1996","unstructured":"Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P . Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996; 98: 610\u2013615.","journal-title":"J Clin Invest"},{"key":"BF6500462_CR103","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A . Reporting results of cancer treatment. Cancer 1981; 47: 207\u2013214.","journal-title":"Cancer"},{"key":"BF6500462_CR104","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/annonc\/mdf035","volume":"13","author":"N Frickhofen","year":"2002","unstructured":"Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M . Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002; 13: 797\u2013801.","journal-title":"Ann Oncol"},{"key":"BF6500462_CR105","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00008571-200004000-00002","volume":"10","author":"ES Collie-Duguid","year":"2000","unstructured":"Collie-Duguid ES, Etienne MC, Milano G, McLeod HL . Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000; 10: 217\u2013223.","journal-title":"Pharmacogenetics"},{"key":"BF6500462_CR106","first-page":"2899","volume":"52","author":"RA Fleming","year":"1992","unstructured":"Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992; 52: 2899\u20132902.","journal-title":"Cancer Res"},{"key":"BF6500462_CR107","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/clinchem\/46.1.9","volume":"46","author":"AB Van Kuilenburg","year":"2000","unstructured":"Van Kuilenburg AB, Van Lenthe H, Tromp A, Veltman PC, Van Gennip AH . Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 2000; 46: 9\u201317.","journal-title":"Clin Chem"},{"key":"BF6500462_CR108","first-page":"2832","volume":"7","author":"M Raida","year":"2001","unstructured":"Raida M, Schwabe W, Hausler P, Van Kuilenburg AB, Van Gennip AH, Behnke D et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2032-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001; 7: 2832\u20132839.","journal-title":"Clin Cancer Res"},{"key":"BF6500462_CR109","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/annonc\/mdg056","volume":"14","author":"AB Van Kuilenburg","year":"2003","unstructured":"Van Kuilenburg AB, Baars JW, Meinsma R, Van Gennip AH . Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene. Ann Oncol 2003; 14: 341\u2013342.","journal-title":"Ann Oncol"},{"issue":"Suppl. 6","key":"BF6500462_CR110","first-page":"101","volume":"25","author":"C Kollmannsberger","year":"2001","unstructured":"Kollmannsberger C, Bokemeyer C, Marx C, Fischer J, Honecker F, Schwab M et al. The association between mutations in the dihydropyrimidine dehydrogenase gene and severe toxicity of the treatment with s-fluorouracil: a prospective multicenter study. Onkologie 2001; 25 (Suppl. 6): 101.","journal-title":"Onkologie"},{"key":"BF6500462_CR111","first-page":"4705","volume":"6","author":"AB van Kuilenburg","year":"2000","unstructured":"van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705\u20134712.","journal-title":"Clin Cancer Res"},{"key":"BF6500462_CR112","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.clpt.2004.01.010","volume":"75","author":"K Sai","year":"2004","unstructured":"Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75: 501\u2013515.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500462_CR113","first-page":"596","volume":"29","author":"F Innocenti","year":"2001","unstructured":"Innocenti F, Iyer L, Ratain MJ . Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos 2001; 29: 596\u2013600.","journal-title":"Drug Metab Dispos"},{"key":"BF6500462_CR114","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/j.1349-7006.2006.00321.x","volume":"97","author":"K Araki","year":"2006","unstructured":"Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 2006; 97: 1255\u20131259.","journal-title":"Cancer Sci"},{"key":"BF6500462_CR115","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","volume":"22","author":"F Innocenti","year":"2004","unstructured":"Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382\u20131388.","journal-title":"J Clin Oncol"},{"key":"BF6500462_CR116","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921\u20136926.","journal-title":"Cancer Res"},{"key":"BF6500462_CR117","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.tips.2006.06.007","volume":"27","author":"ML Maitland","year":"2006","unstructured":"Maitland ML, Vasisht K, Ratain MJ . TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci 2006; 27: 432\u2013437.","journal-title":"Trends Pharmacol Sci"},{"key":"BF6500462_CR118","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/jhep.2002.32102","volume":"35","author":"YS Huang","year":"2002","unstructured":"Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883\u2013889.","journal-title":"Hepatology"},{"key":"BF6500462_CR119","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/oxfordjournals.aje.a010289","volume":"151","author":"N Brockton","year":"2000","unstructured":"Brockton N, Little J, Sharp L, Cotton SC . N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 2000; 151: 846\u2013861.","journal-title":"Am J Epidemiol"},{"key":"BF6500462_CR120","first-page":"1239","volume":"10","author":"S Garte","year":"2001","unstructured":"Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10: 1239\u20131248.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BF6500462_CR121","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000028402","volume":"61","author":"DM Grant","year":"2000","unstructured":"Grant DM, Goodfellow GH, Sugamori KS, Durette K . Pharmacogentics of the human arylamine N-actyltransferases. Pharmacology 2000; 61: 204\u2013211.","journal-title":"Pharmacology"},{"key":"BF6500462_CR122","first-page":"161","volume":"57","author":"H Tiitinen","year":"1968","unstructured":"Tiitinen H et al. Comparison of the isoniazid in activation in Finns and Lapps. Ann Med Int Finn 1968; 57: 161.","journal-title":"Ann Med Int Finn"},{"key":"BF6500462_CR123","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1164\/ajrccm.155.5.9154882","volume":"155","author":"DP Parkin","year":"1997","unstructured":"Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997; 155: 1717\u20131722.","journal-title":"Am J Respir Crit Care Med"},{"key":"BF6500462_CR124","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1248\/bpb.24.544","volume":"24","author":"T Kita","year":"2001","unstructured":"Kita T, Tanigawara Y, Chikazawa S, Hatanaka H, Sakaeda T, Komada F et al. N-Acetyltransferase 2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol Pharm Bull 2001; 24: 544\u2013549.","journal-title":"Biol Pharm Bull"},{"key":"BF6500462_CR125","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1128\/AAC.49.5.1733-1738.2005","volume":"49","author":"M Kinzig-Schippers","year":"2005","unstructured":"Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 2005; 49: 1733\u20131738.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF6500462_CR126","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2165\/00003495-198529040-00003","volume":"29","author":"DWJ Clark","year":"1985","unstructured":"Clark DWJ . Genetically determine variability in acetylation and oxidation: therapeutic implications. Drugs 1985; 29: 342\u2013375.","journal-title":"Drugs"},{"key":"BF6500462_CR127","first-page":"256","volume":"4","author":"M Ohno","year":"2000","unstructured":"Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000; 4: 256\u2013261.","journal-title":"Int J Tuberc Lung Dis"},{"key":"BF6500462_CR128","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/jhep.2002.32102","volume":"35","author":"YS Huang","year":"2002","unstructured":"Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883\u2013889.","journal-title":"Hepatology"},{"key":"BF6500462_CR129","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1086\/424999","volume":"39","author":"PR Donald","year":"2004","unstructured":"Donald PR, Sirgel FA, Venter A, Parkin DP, Seifart HI, van de Wal BW et al. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis 2004; 39: 1425\u20131430.","journal-title":"Clin Infect Dis"},{"key":"BF6500462_CR130","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/sj.tpj.6500361","volume":"6","author":"W Kalow","year":"2006","unstructured":"Kalow W . Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J 2006; 6: 162\u2013165.","journal-title":"Pharmacogenomics J"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/6500462.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500462","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500462.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T06:20:52Z","timestamp":1737094852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6500462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,5]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["BF6500462"],"URL":"https:\/\/doi.org\/10.1038\/sj.tpj.6500462","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,5]]},"assertion":[{"value":"16 August 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2007","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2007","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2007","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}